论文部分内容阅读
微创治疗已经成为中晚期原发性肝癌(HCC)的主要治疗方法之一,但生存率低仍然是治疗的瓶颈。HCC与机体细胞免疫密切相关。HCC患者细胞免疫功能低下,表现为CD4+降低,CD8+升高,CD4+/CD8+倒置、自然杀伤细胞活性降低。调节性T淋巴细胞升高。如何保护、提高HCC患者细胞免疫功能应是微创治疗中的重要方面。测定HCC患者外周血T淋巴细胞亚群的分布情况,可了解HCC患者的机体免疫状况,评估肝癌患者的抗肿瘤免疫功能以及预后,有利于HCC微创治疗方案的选择。细胞免疫状态将是微创物理性治疗的重要内容和研究方向之一。
Minimally invasive treatment has become one of the main treatment of advanced primary liver cancer (HCC), but the low survival rate is still the bottleneck of treatment. HCC is closely related to cellular immunity. HCC patients with poor cellular immunity, manifested as decreased CD4 +, CD8 +, CD4 + / CD8 + inversion, natural killer cell activity decreased. Regulatory T lymphocytes rise. How to protect and improve cellular immune function in patients with HCC should be an important aspect of minimally invasive treatment. To determine the distribution of T lymphocyte subsets in peripheral blood of patients with HCC, to understand the immune status of HCC patients, to evaluate the anti-tumor immune function and prognosis of HCC patients, which is beneficial to the choice of minimally invasive treatment of HCC. Cell immune status will be an important part of minimally invasive physical therapy and research directions.